Topical TXA in total joint replacement lowers blood transfusion use

Orthopedic surgeons have conducted a cost-benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty patients that revealed a 12 percent transfusion rate reduction -- from 17.5 percent to 5.5 percent -- with no significant difference in complication rates.